[Pharmacogenomics of multiple sclerosis: association of immune response genes polymorphism with copaxone treatment efficacy].

E. I. Tsareva; O. G. Kulakova; O. I. Makarycheva; A. N. Boǐko; S. G. Shchur; N. I. Lashch; N. F. Popova; E. I. Gusev; V. V. Bashinskaia; D. V. L'vov; A. V. Favorov; M. F. Ochs; O. O. Favorova

[Pharmacogenomics of multiple sclerosis: association of immune response genes polymorphism with copaxone treatment efficacy].

E. I. Tsareva, O. G. Kulakova, O. I. Makarycheva, A. N. Boǐko, S. G. Shchur, N. I. Lashch, N. F. Popova, E. I. Gusev, V. V. Bashinskaia, D. V. L'vov, A. V. Favorov, M. F. Ochs, O. O. Favorova

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Complex association analysis of copaxone (glatiramer acetate) immunotherapy efficacy with allelic polymorphism in the number of immune response genes, which encode interferone beta (IFNB1), transforming growth factor beta1 (TGFB1), interferone gamma (IFNG), tumor necrosis factor (TNF), interferon alpha/beta receptor 1 (IFNAR1), CC chemokine receptor 5 (CCR5), interleukin 7 receptor alpha subunit (IL7RA), cytotoxic T-lymphocyte antigen 4 (CTLA4) and HLA class II histocompatibility antigen beta chain (DRB1) was performed with APSampler algorithm for 285 multiple sclerosis patients of Russian ethnicity. The results show evidence for the contribution of polymorphic variants in CCRS, DRB1, IFNG, TGFB1, IFNAR1, IL7RA and, probably, TNF and CTLA4 genes to copaxone treatment response. Single alleles of CCR5 and DRB1 genes are reliably associated with treatment efficacy. Carriage of allelic variants of other above mentioned genes contribute with reliable effect to copaxone treatment response as part of bi- and three-allelic combinations only. Present investigation may support basis toward the future possibility of prognostic test realization, which can provide a personal choice of immunomodulatory treatment for a patient with multiple sclerosis.

Original language	English (US)
Pages (from-to)	963-972
Number of pages	10
Journal	Molekuliarnaia biologiia
Volume	45
Issue number	6
State	Published - Nov 2011
Externally published	Yes

ASJC Scopus subject areas

General Medicine

Cite this

Tsareva, E. I., Kulakova, O. G., Makarycheva, O. I., Boǐko, A. N., Shchur, S. G., Lashch, N. I., Popova, N. F., Gusev, E. I., Bashinskaia, V. V., L'vov, D. V., Favorov, A. V., Ochs, M. F., & Favorova, O. O. (2011). [Pharmacogenomics of multiple sclerosis: association of immune response genes polymorphism with copaxone treatment efficacy]. Molekuliarnaia biologiia, 45(6), 963-972.

@article{a795173d3053407986f473285400c4e4,

title = "[Pharmacogenomics of multiple sclerosis: association of immune response genes polymorphism with copaxone treatment efficacy].",

abstract = "Complex association analysis of copaxone (glatiramer acetate) immunotherapy efficacy with allelic polymorphism in the number of immune response genes, which encode interferone beta (IFNB1), transforming growth factor beta1 (TGFB1), interferone gamma (IFNG), tumor necrosis factor (TNF), interferon alpha/beta receptor 1 (IFNAR1), CC chemokine receptor 5 (CCR5), interleukin 7 receptor alpha subunit (IL7RA), cytotoxic T-lymphocyte antigen 4 (CTLA4) and HLA class II histocompatibility antigen beta chain (DRB1) was performed with APSampler algorithm for 285 multiple sclerosis patients of Russian ethnicity. The results show evidence for the contribution of polymorphic variants in CCRS, DRB1, IFNG, TGFB1, IFNAR1, IL7RA and, probably, TNF and CTLA4 genes to copaxone treatment response. Single alleles of CCR5 and DRB1 genes are reliably associated with treatment efficacy. Carriage of allelic variants of other above mentioned genes contribute with reliable effect to copaxone treatment response as part of bi- and three-allelic combinations only. Present investigation may support basis toward the future possibility of prognostic test realization, which can provide a personal choice of immunomodulatory treatment for a patient with multiple sclerosis.",

author = "Tsareva, {E. I.} and Kulakova, {O. G.} and Makarycheva, {O. I.} and Boǐko, {A. N.} and Shchur, {S. G.} and Lashch, {N. I.} and Popova, {N. F.} and Gusev, {E. I.} and Bashinskaia, {V. V.} and L'vov, {D. V.} and Favorov, {A. V.} and Ochs, {M. F.} and Favorova, {O. O.}",

year = "2011",

month = nov,

language = "English (US)",

volume = "45",

pages = "963--972",

journal = "Molekuliarnaia biologiia",

issn = "0026-8984",

publisher = "Russian Academy of Sciences",

number = "6",

}

TY - JOUR

T1 - [Pharmacogenomics of multiple sclerosis

T2 - association of immune response genes polymorphism with copaxone treatment efficacy].

AU - Tsareva, E. I.

AU - Kulakova, O. G.

AU - Makarycheva, O. I.

AU - Boǐko, A. N.

AU - Shchur, S. G.

AU - Lashch, N. I.

AU - Popova, N. F.

AU - Gusev, E. I.

AU - Bashinskaia, V. V.

AU - L'vov, D. V.

AU - Favorov, A. V.

AU - Ochs, M. F.

AU - Favorova, O. O.

PY - 2011/11

Y1 - 2011/11

N2 - Complex association analysis of copaxone (glatiramer acetate) immunotherapy efficacy with allelic polymorphism in the number of immune response genes, which encode interferone beta (IFNB1), transforming growth factor beta1 (TGFB1), interferone gamma (IFNG), tumor necrosis factor (TNF), interferon alpha/beta receptor 1 (IFNAR1), CC chemokine receptor 5 (CCR5), interleukin 7 receptor alpha subunit (IL7RA), cytotoxic T-lymphocyte antigen 4 (CTLA4) and HLA class II histocompatibility antigen beta chain (DRB1) was performed with APSampler algorithm for 285 multiple sclerosis patients of Russian ethnicity. The results show evidence for the contribution of polymorphic variants in CCRS, DRB1, IFNG, TGFB1, IFNAR1, IL7RA and, probably, TNF and CTLA4 genes to copaxone treatment response. Single alleles of CCR5 and DRB1 genes are reliably associated with treatment efficacy. Carriage of allelic variants of other above mentioned genes contribute with reliable effect to copaxone treatment response as part of bi- and three-allelic combinations only. Present investigation may support basis toward the future possibility of prognostic test realization, which can provide a personal choice of immunomodulatory treatment for a patient with multiple sclerosis.

AB - Complex association analysis of copaxone (glatiramer acetate) immunotherapy efficacy with allelic polymorphism in the number of immune response genes, which encode interferone beta (IFNB1), transforming growth factor beta1 (TGFB1), interferone gamma (IFNG), tumor necrosis factor (TNF), interferon alpha/beta receptor 1 (IFNAR1), CC chemokine receptor 5 (CCR5), interleukin 7 receptor alpha subunit (IL7RA), cytotoxic T-lymphocyte antigen 4 (CTLA4) and HLA class II histocompatibility antigen beta chain (DRB1) was performed with APSampler algorithm for 285 multiple sclerosis patients of Russian ethnicity. The results show evidence for the contribution of polymorphic variants in CCRS, DRB1, IFNG, TGFB1, IFNAR1, IL7RA and, probably, TNF and CTLA4 genes to copaxone treatment response. Single alleles of CCR5 and DRB1 genes are reliably associated with treatment efficacy. Carriage of allelic variants of other above mentioned genes contribute with reliable effect to copaxone treatment response as part of bi- and three-allelic combinations only. Present investigation may support basis toward the future possibility of prognostic test realization, which can provide a personal choice of immunomodulatory treatment for a patient with multiple sclerosis.

UR - http://www.scopus.com/inward/record.url?scp=84873021372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873021372&partnerID=8YFLogxK

M3 - Article

C2 - 22295566

AN - SCOPUS:84873021372

SN - 0026-8984

VL - 45

SP - 963

EP - 972

JO - Molekuliarnaia biologiia

JF - Molekuliarnaia biologiia

IS - 6

ER -

[Pharmacogenomics of multiple sclerosis: association of immune response genes polymorphism with copaxone treatment efficacy].

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this